Back to search
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
Data up to Jan 2025
Published2008
Citations159
References0
Total Citations Per Year
Abstract
References (0)
No references found
Cited By (0)
No citing papers found in database